{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anderson+Fabry+Disease&page=3",
    "query": {
      "condition": "Anderson Fabry Disease",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 97,
    "total_pages": 10,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anderson+Fabry+Disease&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Anderson+Fabry+Disease&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T21:53:09.526Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00001491",
      "title": "Analysis of the Nervous System in Patients With Fabry's Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fabry's Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 325,
      "start_date": "1995-05-11",
      "completion_date": "2008-03-03",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-10-08T21:53:09.526Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001491"
    },
    {
      "nct_id": "NCT05186324",
      "title": "Fabry Patient's Experience Of PegunigaLsidasE Alfa Monthly Infusion",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "Interview",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 23,
      "start_date": "2022-01-26",
      "completion_date": "2022-08-31",
      "has_results": false,
      "last_update_posted_date": "2023-03-21",
      "last_synced_at": "2026-10-08T21:53:09.526Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05186324"
    },
    {
      "nct_id": "NCT00230607",
      "title": "Study of the Effects of Fabrazyme Treatment on Lactation and Infants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fabry Disease",
        "Alpha Galactosidase A Deficiency"
      ],
      "interventions": [
        {
          "name": "agalsidase beta",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 7,
      "start_date": "2006-05-28",
      "completion_date": "2024-02-09",
      "has_results": true,
      "last_update_posted_date": "2024-04-10",
      "last_synced_at": "2026-10-08T21:53:09.526Z",
      "location_count": 3,
      "location_summary": "Decatur, Georgia • Fairfax, Virginia • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00230607"
    },
    {
      "nct_id": "NCT00526071",
      "title": "Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "migalastat HCl",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2007-09-17",
      "completion_date": "2012-09-08",
      "has_results": true,
      "last_update_posted_date": "2018-10-03",
      "last_synced_at": "2026-10-08T21:53:09.526Z",
      "location_count": 3,
      "location_summary": "Decatur, Georgia • New York, New York • Dallas, Texas",
      "locations": [
        {
          "city": "Decatur",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00526071"
    },
    {
      "nct_id": "NCT02795676",
      "title": "Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "PRX-102 (pegunigalsidase alfa)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "agalsidase beta",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Protalix",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 78,
      "start_date": "2016-06",
      "completion_date": "2022-07",
      "has_results": true,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-10-08T21:53:09.526Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Orange, California + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02795676"
    },
    {
      "nct_id": "NCT00081497",
      "title": "A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "agalsidase beta",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2004-01",
      "completion_date": "2005-09",
      "has_results": true,
      "last_update_posted_date": "2015-04-02",
      "last_synced_at": "2026-10-08T21:53:09.526Z",
      "location_count": 18,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "West Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Coral Springs",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00081497"
    },
    {
      "nct_id": "NCT02000310",
      "title": "Molecular and Cellular Mechanisms of Lysosomal Storage Diseases",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Lysosomal Storage Disorders"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "O & O Alpan LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "1 Day to 100 Years"
      },
      "enrollment_count": 80,
      "start_date": "2013-11",
      "completion_date": "2022-12",
      "has_results": false,
      "last_update_posted_date": "2021-02-23",
      "last_synced_at": "2026-10-08T21:53:09.526Z",
      "location_count": 1,
      "location_summary": "Fairfax, Virginia",
      "locations": [
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02000310"
    },
    {
      "nct_id": "NCT01031173",
      "title": "Treatment Protocol of Replagal for Patients With Fabry Disease",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "agalsidase alfa",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2021-05-24",
      "last_synced_at": "2026-10-08T21:53:09.526Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01031173"
    },
    {
      "nct_id": "NCT01489995",
      "title": "Migalastat Food Effect Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "A (migalastat)",
          "type": "DRUG"
        },
        {
          "name": "B (migalastat)",
          "type": "DRUG"
        },
        {
          "name": "C (migalastat)",
          "type": "DRUG"
        },
        {
          "name": "D (migalastat)",
          "type": "DRUG"
        },
        {
          "name": "E (migalastat)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2011-10",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2013-12-18",
      "last_synced_at": "2026-10-08T21:53:09.526Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01489995"
    },
    {
      "nct_id": "NCT05039866",
      "title": "Long-Term Follow-up of Subjects Who Were Treated With ST-920",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fabry Disease",
        "Fabry Disease, Cardiac Variant"
      ],
      "interventions": [
        {
          "name": "ST-920",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sangamo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2021-08-16",
      "completion_date": "2039-03",
      "has_results": false,
      "last_update_posted_date": "2026-08-20",
      "last_synced_at": "2026-10-08T21:53:09.526Z",
      "location_count": 8,
      "location_summary": "Irvine, California • Tampa, Florida • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05039866"
    }
  ]
}